These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1278088)

  • 1. [Clinical and biochemical considerations on depressive states occuring during parkinsonian syndrome treated by L-Dopa].
    Gisselmann A; Boudry C; Marin A; Ballivet J
    Encephale; 1976; 2(2):105-13. PubMed ID: 1278088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Results after 3 to 5 years of treatment of 219 cases of Parkinson's syndrome treated by L-Dopa and an L-Dopa -decarboxylase inhibitor combination].
    Boudin G; Pepin B; Guillard A; Godlewski S; Fabiani JM; Haguenau M
    Rev Neurol (Paris); 1974; 130(7-8):273-84. PubMed ID: 4217929
    [No Abstract]   [Full Text] [Related]  

  • 3. [Trial use of L-dopa associated with a dopa-decarboxylase inhibitor in Parkinson's syndrome].
    Carotti A; Tomassetti G; Lucciarini L; Barone G; Mugnai A
    Clin Ter; 1974 Jul; 70(1):9-15. PubMed ID: 4153252
    [No Abstract]   [Full Text] [Related]  

  • 4. [Aspects of long-term treatment with levodopa alone and levodopa combined with dopa decarboxylase inhibitors].
    Cinca I; Serbănescu A; Tudorache B
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1982; 27(4):261-70. PubMed ID: 6222452
    [No Abstract]   [Full Text] [Related]  

  • 5. [Experience with a l-dopa retard preparation in the peroral long-term therapy of the Parkinsonian syndrome].
    Binder H; Gerstenbrand F; Grünberger J; Gründig E; Schubert H
    Nervenarzt; 1976 Nov; 47(11):656-60. PubMed ID: 826840
    [No Abstract]   [Full Text] [Related]  

  • 6. [The L-dopa test in Parkinson's disease].
    Esteguy M; Bonnet AM; Kefalos J; Lhermitte F; Agid Y
    Rev Neurol (Paris); 1985; 141(5):413-5. PubMed ID: 4048732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
    Admani AK; Verma S; Cordingley GJ; Harris RI
    Pharmatherapeutica; 1985; 4(2):132-40. PubMed ID: 4059292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Variations of the therapeutic action (on-off phenomenon) in patients with Parkin].
    Carolei A; Casacchi M; Fazio C
    Clin Ter; 1977 Jan; 80(2):181-9. PubMed ID: 844268
    [No Abstract]   [Full Text] [Related]  

  • 9. [Variation in the pharmacologic affects of decarboxylase inhibitor in variable doses in man].
    Castaigne P; Rondot P; Taberlet A; Baumann N
    Biomedicine; 1974 Dec; 21(12):486-90. PubMed ID: 4462871
    [No Abstract]   [Full Text] [Related]  

  • 10. [Analysis of a therapeutic failure of L-Dopa: can Adams-Van Bosaert and Van Der Eecken's strio-nigral degeneration be diagnosed during the patient's life?].
    André JM; Royer RJ; Duc M; Kissel P
    Rev Neurol (Paris); 1974; 130(7-8):322-6. PubMed ID: 4453761
    [No Abstract]   [Full Text] [Related]  

  • 11. Response of tardive and L-dopa-induced dyskinesias to antidepressants.
    el-Awar M; Freedman M; Seeman P; Goldenberg L; Little J; Solomon P
    Can J Neurol Sci; 1987 Nov; 14(4):629-31. PubMed ID: 3690436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Review of problems in the treatment of the parkinsonian syndrome with L-dopa].
    Piccirilli M; Quartesan R
    Clin Ter; 1976 Mar; 76(5):467-77. PubMed ID: 991553
    [No Abstract]   [Full Text] [Related]  

  • 13. [Side-effects of L-dopa therapy].
    Girke W; Xenakis Ch
    Dtsch Med Wochenschr; 1975 Oct; 100(42):2165-9. PubMed ID: 1100342
    [No Abstract]   [Full Text] [Related]  

  • 14. [Secondary effects of prolonged levodopa therapy in Parkinson's disease].
    Peiró Grasa A; Grau-Veciana JM
    Med Clin (Barc); 1985 Jun; 85(3):88-91. PubMed ID: 4021630
    [No Abstract]   [Full Text] [Related]  

  • 15. [Modifications of catecholamine metabolism under the effect of a decarboxylase inhibitor associated with L-dopa and desipramine in patients with depressive and parkinsonian syndromes].
    Geissbuhler F; Bartholini G; Gaillard JM; Tissot R
    Encephale; 1971; 60(3):189-209. PubMed ID: 5119348
    [No Abstract]   [Full Text] [Related]  

  • 16. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical aspects and pathogenesis of the "on-off" phenomenon in Parkinson syndrome].
    Jörg J; Schneider I
    Fortschr Neurol Psychiatr; 1988 Jan; 56(1):22-34. PubMed ID: 3126121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The problem of side effects after a treatment with L-dopa in the Parkinson's syndrome: clinical and animal studies (author's transl)].
    Sommer H; Fischer GJ; Quandt J
    Folia Clin Int (Barc); 1974 Oct; 24(10):681-95. PubMed ID: 4279185
    [No Abstract]   [Full Text] [Related]  

  • 19. Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys.
    Rupniak NM; Boyce S; Steventon MJ; Iversen SD; Marsden CD
    Ann Neurol; 1992 Jul; 32(1):103-5. PubMed ID: 1642462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone (author's transl)].
    Agid Y; Quinn N; Lhermitte F
    Rev Neurol (Paris); 1981; 137(1):49-51. PubMed ID: 7232966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.